Phase III study of vinorelbine plus epirubicin versus epirubicin alone in first-line chemotherapy of metastatic breast cancer:: An Scandinavian breast group study (SBG9403)

被引：0
|
作者：
Ejlertsen, B
Mouridsen, HT
Langkjer, ST
Andersen, J
Sjöström, J
Kjaer, M
机构：
来源：
BRITISH JOURNAL OF CANCER | 2003年 / 88卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S19 / S19
页数：1
相关论文
共 50 条
  • [1] Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer:: A Scandinavian breast group trial (SBG9403)
    Ejlertsen, B
    Mouridsen, HT
    Langkjer, ST
    Andersen, J
    Sjöström, J
    Kjaer, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) : 2313 - 2320
  • [2] Epirubicin and vinorelbine versus single agent epirubicin as first line chemotherapy in metastatic breast cancer
    Ejlertsen, B
    Mouridsen, H
    Langkjer, ST
    Andersen, J
    Sjostrom, J
    Kjaer, M
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S66 - S67
  • [3] Randomized multicenter phase III study of epirubicin/paclitaxel versus epirubicin/cyclophosphamide in first-line treatment of metastatic breast cancer:: A study of the AGO Breast Cancer Study Group
    Lück, HJ
    Thomssen, C
    Kuhn, W
    Eidtmann, H
    du Bois, A
    Möbus, V
    Untch, M
    Jackisch, C
    Olbricht, S
    Schröder, W
    Richter, B
    Bauknecht, T
    Köhler, C
    Schulz, R
    von Minckwitz, G
    Blohmer, J
    SEMINARS IN ONCOLOGY, 1999, 26 (06) : 8 - 8
  • [4] First-line treatment with epirubicin and vinorelbine in metastatic breast cancer
    Vici, P
    Colucci, G
    Gebbia, V
    Amodio, A
    Giotta, F
    Belli, F
    Conti, F
    Gebbia, N
    Pezzella, G
    Valerio, MR
    Brandi, M
    Pisconti, S
    Durini, E
    Giannarelli, D
    Lopez, M
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (11) : 2689 - 2694
  • [5] Oral vinorelbine versus intravenous vinorelbine, in combination with epirubicin as first-line chemotherapy in Chinese patients with metastatic breast cancer
    Huang, Liang
    Wang, Xiaojia
    Zhou, Liheng
    Di, Lijun
    Zheng, Hongyu
    Jiang, Zefei
    Wang, Yongsheng
    Song, Xiangqun
    Feng, Jifeng
    Yu, Shiying
    Liu, Yunpeng
    Zheng, Hong
    Shen, Kunwei
    Tong, Zhongsheng
    Shao, Zhimin
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (01) : 205 - 215
  • [6] Oral vinorelbine versus intravenous vinorelbine, in combination with epirubicin as first-line chemotherapy in Chinese patients with metastatic breast cancer
    Liang Huang
    Xiaojia Wang
    Liheng Zhou
    Lijun Di
    Hongyu Zheng
    Zefei Jiang
    Yongsheng Wang
    Xiangqun Song
    Jifeng Feng
    Shiying Yu
    Yunpeng Liu
    Hong Zheng
    Kunwei Shen
    Zhongsheng Tong
    Zhimin Shao
    Cancer Chemotherapy and Pharmacology, 2020, 85 : 205 - 215
  • [7] Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study
    Nielsen, D
    Dombernowsky, P
    Larsen, SK
    Hansen, OP
    Skovsgaard, T
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 46 (06) : 459 - 466
  • [8] Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study
    Dorte Nielsen
    Per Dombernowsky
    Susanne Kornum Larsen
    Ole Paaske Hansen
    Torben Skovsgaard
    Cancer Chemotherapy and Pharmacology, 2000, 46 : 459 - 466
  • [9] Combined epirubicin and vinorelbine as first-line therapy in metastatic breast cancer: a pilot study performed by the Danish Breast Cancer Cooperative Group
    Ejlertsen, B
    Hojris, I
    Hansen, S
    Moholt, K
    Kristensen, B
    Mouridsen, HT
    Andersen, J
    Rose, C
    Kjaer, M
    BREAST, 2003, 12 (01): : 42 - 50
  • [10] Mitomycin (M), epirubicin (E) and vinorelbine (V) first-line chemotherapy for metastatic breast cancer (MBC). A feasibility study
    Neri, A
    Guarnieri, A
    Tucci, E
    Pepi, F
    Mazzocchi, B
    Algeri, R
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S44 - S44
12345